Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

@article{Kaufman2005TargetingTL,
  title={Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.},
  author={Howard L. Kaufman and Gail Deraffele and Josephine Mitcham and Dorota N. Moroziewicz and Seth M Cohen and Karl S. Hurst-Wicker and Ken Cheung and David Sc Lee and Joseph DiVito and Magalese Voulo and Julie Donovan and Kate Dolan and Kelledy H. Manson and Dennis L. Panicali and Ena Wang and Heidi Hoerig and Francesco M. Marincola},
  journal={The Journal of clinical investigation},
  year={2005},
  volume={115 7},
  pages={1903-12}
}
Immunotherapy for the treatment of metastatic melanoma remains a major clinical challenge. The melanoma microenvironment may lead to local T cell tolerance in part through downregulation of costimulatory molecules, such as B7.1 (CD80). We report the results from the first clinical trial, to our knowledge, using a recombinant vaccinia virus expressing B7.1 (rV-B7.1) for monthly intralesional vaccination of accessible melanoma lesions. A standard 2-dose-escalation phase I clinical trial was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 69 references

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma

  • P Triozzi
  • Hum. Gene Ther
  • 2005

High-frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma

  • G Hofbauer
  • J. Immunother
  • 2004

Similar Papers

Loading similar papers…